Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers
Stopped Company's desire to allocate more research and development resources to other clinical programs. Decision not driven by any safety concerns.
Conditions
- Chronic Diabetic Foot Ulcers
Interventions
- BIOLOGICAL: CHAM
- OTHER: Control
Sponsor
Osiris Therapeutics